HOUSTON--(BUSINESS WIRE)--Qbtech, the global leader in objective ADHD testing, today announced the launch of its new grant program, QbAccess. Created to make ADHD testing and care more accessible to underserved populations, the program provides non-profit healthcare organizations with access to Qbtech’s FDA-cleared objective ADHD testing devices at a reduced rate..

休斯顿--（商业新闻短讯）--客观ADHD测试的全球领导者Qbtech今天宣布启动其新的资助计划QbAccess。该计划旨在使服务不足的人群更容易获得ADHD测试和护理，该计划为非营利性医疗保健组织提供了以较低的速度获得Qbtech FDA批准的客观ADHD测试设备的机会。。

Non-profit clinics serve an estimated 40 million people each year, with 90% of the patients living at or below 200% of the federal poverty level. The goal of QbAccess is to help reduce health disparities by ensuring low-income populations have access to high-quality ADHD evaluation services to improve clinical outcomes.

据估计，非营利性诊所每年为4000万人提供服务，其中90%的患者生活在联邦贫困线的200%或以下。QbAccess的目标是通过确保低收入人群能够获得高质量的ADHD评估服务来改善临床结果，从而帮助减少健康差异。

Through the program, non-profit healthcare organizations, including Federally Qualified Healthcare Centers (FQHCs) and Tribal Clinics, can apply for grant funding to receive access to Qbtech’s objective ADHD testing technology..

通过该计划，包括联邦合格医疗保健中心（FQHCs）和部落诊所在内的非营利性医疗保健组织可以申请赠款，以获得Qbtech的客观ADHD测试技术。。

“The launch of QbAccess is another milestone for Qbtech and aligns with our mission to improve the lives of those with ADHD,” said Qbtech CEO Carl Reuterskiöld. “With this program, we hope to reach critical populations in the U.S. where better mental and behavioral healthcare is needed, especially for those suffering from undiagnosed or untreated ADHD.

Qbtech首席执行官卡尔·雷特斯基（CarlReuterskiöld）表示：“QbAccess的推出是Qbtech的另一个里程碑，符合我们改善多动症患者生活的使命。”。“通过这项计划，我们希望能够接触到需要更好的心理和行为保健的美国关键人群，特别是那些未经诊断或未经治疗的多动症患者。

Coupled with our team’s advocacy work to maintain and improve remote ADHD care, we believe we can truly make an impactful difference.”.

再加上我们团队维护和改善远程ADHD护理的倡导工作，我们相信我们能够真正做出有影响力的改变。”。

The concept for QbAccess stemmed from Qbtech’s Company Days 2023, where employees were given the opportunity to present ideas that would enhance innovation or create additional pathways to improve the lives of ADHD patients. After presentations to company leadership and the Board of Directors, QbAccess was selected for its alignment with Qbtech’s company values..

QbAccess的概念源于Qbtech的2023年公司日，员工有机会提出可以增强创新或创造其他途径来改善ADHD患者生活的想法。在向公司领导层和董事会介绍后，QbAccess因其与Qbtech公司价值观的一致性而被选中。。

Anna Brasile, US Senior Business Development Manager at Qbtech, spearheaded this initiative and shared that “from my past clinical experience with patients from underserved communities and in my current work with non-profit clinics, there has been a lack of resources to implement thorough evaluations and treatment monitoring.

Qbtech美国高级业务开发经理安娜·布拉西尔（AnnaBrasile）率先提出了这一倡议，并分享了“根据我过去与服务不足社区患者的临床经验以及我目前在非营利性诊所的工作，缺乏资源来实施彻底的评估和治疗监测。

QbAccess aims to reduce barriers to care for those who need it most.”.

QbAccess旨在减少照顾最需要的人的障碍。”。

“QbAccess is just the first of what we hope are many initiatives we launch from within our walls. We look forward to awarding our first grant from the program and are excited to hear how we can help applicants in the future,” added Reuterskiöld. “We are proud of all the employees who presented ideas during last year’s Company Days and are thrilled with the conversations, ideas and innovations it has inspired among our team.”.

。“我们为所有在去年的公司日子里提出想法的员工感到骄傲，并为其在我们团队中激发的对话、想法和创新感到兴奋。”。

Transforming ADHD care through its technology-first approach, Qbtech’s objective ADHD tests seamlessly integrate into clinical pathways to facilitate a comprehensive diagnosis, as well as more accurately and efficiently determine treatment effects. Available in-clinic and via telehealth, the devices measure motor activity down to the millimeter and aid in evaluating the core symptoms of ADHD – hyperactivity, inattention, and impulsivity – through a 15-20-minute computer-based test.

Qbtech的客观ADHD测试通过其技术领先的方法将ADHD护理转变为无缝集成到临床路径中，以促进全面诊断，并更准确有效地确定治疗效果。该设备可用于临床和远程保健，可测量运动活动至毫米，并通过15-20分钟的计算机测试帮助评估多动症的核心症状-多动症，注意力不集中和冲动。

Results are instantly presented in a report that compares a patient's results with an age and sex-at-birth-matched control group without ADHD. The highly visual representation of symptoms, shown as graphs and images on the reports, helps patients see their symptoms clearly, bringing transparency into the diagnostic and treatment management process..

结果立即出现在一份报告中，该报告将患者的结果与出生时的年龄和性别相匹配的无ADHD对照组进行了比较。症状的高度视觉表现，如报告中的图形和图像所示，有助于患者清楚地看到他们的症状，从而为诊断和治疗管理过程带来透明度。。

Since its launch in Sweden in 2002, Qbtech has expanded globally. More than 40 independent studies document the company’s benefits across the patient care pathway, including improved access to care, elevated clinician confidence, a 50% better indication of treatment effects than self-rating, and standardization of care across multiple disciplines..

自2002年在瑞典推出以来，Qbtech已在全球范围内扩张。超过40项独立研究记录了该公司在整个患者护理途径中的益处，包括改善了获得护理的机会，提高了临床医生的信心，比自我评估更好地指示了50%的治疗效果，以及跨多个学科的护理标准化。。

Non-profit clinics are encouraged to apply at www.qbtech.com.

鼓励非营利性诊所在www.qbtech.com上申请。

About Qbtech

关于Qbtech

Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 13 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the ‘Best Mental Health Partnership with the NHS.’ For more information about Qbtech, visit www.qbtech.com..

Qbtech成立于2002年，是一家瑞典私营公司，开发了领先的解决方案和产品，用于改善ADHD患者的识别，诊断，治疗和随访。Qbtech在13个国家开展业务，并在斯德哥尔摩、休斯顿和伦敦设有办事处。Qbtech是一家因其创新而备受赞誉的获奖公司，最近一次获得2022年HSJ合作奖，表彰其“与NHS的最佳心理健康合作伙伴关系”有关Qbtech的更多信息，请访问www.Qbtech.com。。